Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  Behr, Thomas M ^a   Wörmann, Bernhard ^a   Gramatzki, Martin ^b   Riggert, Joachim ^a   Gratz, Stefan ^a   Béhé, Martin ^a   Griesinger, Frank ^a   Sharkey, Robert M ^d   Kolb, Hans J ^c   Hiddemann, Wolfgang ^a   Goldenberg, David M ^d   Becker, Wolfgang ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d GARDEN STATE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD22 ANTIGEN; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LL 2 I 131; RITUXIMAB; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; B LYMPHOCYTE; CLINICAL ARTICLE; CONFERENCE PAPER; DOSIMETRY; FEMALE; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REMISSION;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CELL ADHESION MOLECULES; FEMALE; HUMANS; LECTINS; LYMPHOMA, B-CELL; MALE; MICE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; RECOMBINANT FUSION PROTEINS;

EID: 0345425664     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Barclay, A. N., Beyers, A. D., Birkeland, M. L., Brown, M. H., Davis, S. J., Somoza, C., and Williams, A. F. The Leukocyte Antigen Facts Book. London: Academic Press, 1993.
2. DeVita, V. T., Hellman, S., and Rosenberg, S. A. (eds.). Cancer: Principles and Practice of Oncology, Ed. 5. Philadelphia: J. B. Lippincott, 1997.
3. Press, O. W., Howell-Clark, J., Anderson, S., and Bernstein, I. Retention of B-cell specific monoclonal antibodies by human lymphoma cells. Blood, 83: 1390-1397, 1994.
4. Shih, L. B., Lu, H. H. Z., Xuan, H., and Goldenberg, D. M. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int. J. Cancer, 56: 538-545, 1994.
5. Shan, D., and Press, O. W. Constitutive endocytosis and degradation of CD22 by human B cells. J. Immunol., 154: 4466-4475, 1995.
6. Pawlak-Byczkowska, E. J., Hansen, H. J., Dion, A. S., and Goldenberg, D. M. Two new monoclonal antibodies reactive with human lymphoma. Cancer Res., 49: 4568-4577, 1989.
7. Goldenberg, D. M., Horowitz, J. A., Sharkey, R. M., Hall, T. C., Murthy, S., Goldenberg, H., Lee, R. E., Stein, R., Siegel, J. A., Izon, D. O., Burger, K., Swayne, L. C., Belisle, E., Hansen, H. J., and Pinsky, C. M. Targeting, dosimetry and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J. Clin. Oncol., 9: 548-564, 1991.
8. Becker, W., Behr, T., Cumme. F., Rößler, W., Wendler, J., Kern, P., Gramatzki, M., Kalden, J. R., Goldenberg, D. M., and Wolf, F. Ga-67 citrate versus Tc-99m-labelled LL2-Fab′-fragments (anti-CD22) in the staging of B-cell-non-Hodgkin's lymphoma. Cancer Res., 55: 5771-5773, 1995.
9. Juweid, M., Sharkey, R. M., Markowitz, A., Behr, T., Swayne, L. C., Hansen, H. J., Shevitz, J., Leung, S., Rubin, A. D., Herskovic, T., Hanley, D., and Goldenberg, D. M. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res., 55: 5899-5907, 1995.
10. Juweid, M., Sharkey, R. M., Markowitz, A., Behr, T., Swayne, L. C., Hansen, H. J., Shevitz, J., Leung, S., Rubin, A. D., Herskovic, T., Hanley, D., and Goldenberg, D. M. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res., 55: 5899-5907, 1995.
11. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., Matthews, D. C., Fisher. L. D., and Bernstein, I. D. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329: 1219-1224, 1993.
12. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphoma. Lancet, 346: 336-340, 1995.
13. Press, O. W., Eary, J. F., Appelbaum, F. R., and Bernstein, I. D. Treatment of relapsed B cell lymphoma with high-dose radioimmunotherapy and bone marrow transplantation. In: D. M. Goldenberg (ed.), Cancer Therapy with Radiolabeled Antibodies, pp. 229-237. Boca Raton, FL: CRC Press, 1995.
14. 131lI]anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1993.
15. Wahl, R. L., Zasadny, K. R., MacFarlane, D., Francis, I. R., Ross, C. W., Estes, J., Fisher, S., Regan, D., Kroll, S., and Kaminski, M. S. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan phase-I experience. J. Nucl. Med., 39: 21S-27S, 1998.
16. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D., and Dallaire, B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol., 16: 2825-2833, 1998.
17. 99mTc-labeling kit for antibody imaging. Cancer Res., 50: 794-798, 1990.
18. Weadock, K. S., Sharkey, R. M., Varga, D. C., and Goldenberg, D. M. Evaluation of a remote radioiodination system for radioimmunotherapy. J. Nucl. Med., 31: 508-511, 1990.
19. Behr, T. M., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Siegel, J. A., and Goldenberg, D. M. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of CEA-expressing tumors. Cancer Res., 50: 1805-1816, 1996.
20. Siegel, J. A., Lee, R. E., Pawlyk, D. A., Horowitz, J. A., Sharkey, R. M., and Goldenberg, D. M. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Nucl. Med. Biol., 16: 553-559, 1989.
21. Behr, T. M., Dunn, R. M., Gratz, S., Weber, E., Herrmann, A., and Becker, W. An automated scheme for internal radiation dosimetry in nuclear therapy: gamma- or bremsstrahlung-based dose calculation in the therapy of differentiated thyroid cancer, radio-synoviorthesis, bone pain palliation and radioimmunotherapy. J. Nucl. Med., 38: 225P, 1997.
22. Stabin, M. G. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med., 37: 538-546, 1996.
23. Jurcic, J. G., Caron, P. C., Nikula, T. K., Papadopoulos, E. B., Finn, R. D., Gansow, O. A., Miller, W. H., Jr., Geerlings, M. W., Warrell, R. P., Jr., Larson, S. M., and Scheinberg, D. A. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res., 55: 5908-5910, 1995.
24. Behr, T. M., Wulst, E., Radetzky, S., Blumenthal, R. D., Dunn, R. M., Gratz, S., Rave-Fränk, M., Schmidberger, H., Raue, F., and Becker, W. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res., 57: 5309-5319, 1997.